Alzheimer's Disease Medications
February 19, 2026
321
25
6
9.66%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Dr John Kruse Episodes Around February 19, 2026
See what was published immediately before and after this episode.
20:28Now PlayingAlzheimer's Disease Medications
Chapters
YouTube Description
as posted by the channelMain Chapters:
For decades, Alzheimer’s disease, the most common form of dementia, could only be definitively diagnosed by brain biopsy or after death via autopsy, and we had no medications to treat it. Thirty years ago (1994), the FDA approved Cognex (tacrine), the first drug to treat Alzheimer’s disease. Over the next few years, three additional acetylcholinesterase inhibitors reached the market. Pervasive loss of neurons using acetylcholine characterizes Alzheimer’s, and these drugs boost levels of acetylcholine. But they don’t change the course of the disease, only slow progression of dementia by a tiny extent, and frequently have side effects.
A decade later, with the approval of memantine (Namenda), we had another way to try to combat Alzheimer’s. Memantine blocks the NMDA type of glutamate receptors, thereby reducing neuronal over-excitation and consequent cell death. But at best, the course of the disease is only slowed, not reversed.
More recently human monoclonal antibodies directed at amyloid-beta were approved by the FDA. However the makers of the first such drug aducanamab (Aduhelm) announced this month (February 2024) that they will cease production by the end of the year. Leqembi (Iecanemab), which has shown more benefit for preserving cognitive function, remains on the market. These drugs slow the rate of decline more definitively than the earlier drugs, but so far their ability to clear amyloid plaques from the brain is more robust than their clinical effect in improving the course of Alzheimer’s disease.
-----
Free link to my Medium Article on Alzheimer's Disease Medications:
Follow on Medium for hundreds of full length articles on this subject and more!
Access to Full Medium articles requires paid membership.
-----
References:
Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review (2024)
Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review (2022)
Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease (2024)
2023 Alzheimer's disease facts and figures
Tacrine: First Drug Approved for Alzheimer's Disease (1994)
Full Chapter list:
Streamed live February 7, 2024
-------------------------
Psychiatrist, neuroscientist, and author John Kruse, MD, PhD presents practical, actionable, well-researched information about treatment options that scientists and clinicians recommend for adult ADHD and other mental health conditions.
Subscribe if you're curious about how neuroatypical brains can optimize their functioning in our shared, and somewhat strange, world.
ADHD topics have a pink background, and those on more general mental health topics have a purple background. A small collection of Politics related videos have an orange background.
Dr. Kruse has posted videos in the "Videos", "Live", and "Shorts", sections of this channel.
You're welcome to email him with topics you want discussed or people you think he should interview.
drjohnkruse@gmail.com
#health #mentalhealth #alzheimer #dementia #medication
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.